OAR@UM Collection:
/library/oar/handle/123456789/40247
2026-06-19T13:33:32ZA study of the cost-effectiveness of colorectal cancer screening in the Maltese Islands.
/library/oar/handle/123456789/40354
Title: A study of the cost-effectiveness of colorectal cancer screening in the Maltese Islands.
Abstract: This study purports to investigate the cost-effectiveness of a possible national colorectal
cancer screening programme, the general public's awareness of the condition, its
prevalence and risks, the possible rate of compliance and the reasons for non-compliance
if ever such a programme were to take off. Screening would be offered to all those aged
50 to 69, comprising 20.9% or 80,000 of the Maltese population. The initial screening
test would be faecal occult blood testing every 2 years. The programme, administered by
a newly set up screening centre would invite 10,000 every quarter. The compliance rate
would be in the region of 50%. The invitation and test kit would be sent by post some
time before the beginning of each quarter. Those with a positive initial screen (2%)
would be recalled for assessment, resulting in 100 investigations every quarter.
Deviation in the compliance rate would affect resources and costs. Colonoscopy and
possible double-contrast barium enema (DCBE) would be used for further investigation -
both procedures being carried out by highly skilled professionals to significantly reduce
possible mortality from colonoscopy which has been quoted at 0.02%. All professionals
involved would be co-ordinated by a programme manager and quality assurance would
form an integral part of the whole programme. The total cost of the programme would
reach LM230, 120 per year. Given an overall uptake rate of 50% and a test sensitivity of
60%, 30% of all cancers in this age bracket (50-69 years) would be detected. These add
up to 50 cancer cases and 230 new cases of adenomas. Added life expectancy for those
with cancer would range between 2 and 1.35 years; so the cost per life year gained would
fluctuate between LM2,301 and LM3,400. This is a small but significant benefit.
Description: M.SC. PUBLIC HEALTH2001-01-01T00:00:00ZThe role of the mesolimbic dopamine system in interferon-α mediated anhedonia
/library/oar/handle/123456789/32266
Title: The role of the mesolimbic dopamine system in interferon-α mediated anhedonia
Abstract: SAMMUT, S. The role of the mesolimbic dopamine system in Interferon-a
mediated anhedonia
Changes in sucrose intake were used as a measure of anhedonia. Non-drug
manipulations confirmed that the differences observed in the sucrose concentration-intake
curve between the single-bottle and three-bottle were not due to aversion or
satiety but more likely attributable to an effort to regulate reward to an optimal level.
In the single-bottle test increasing hours of deprivation prior to sucrose tests, nonspecifically
altered sucrose intake, while increasing the response-force requirement to
access the sucrose solutions decreased the consumption of the 1 % solution and
increased the intake of the 32% solution, effectively shifting the bell-shaped response reward
curve to the right. This effect was attributed to the motivational drive
associated with the perceived reward value of the sucrose solution on offer.
Sucrose intake is subject to modulation by several neurotransmitters including
DAergic as evident by the effects of raclopride (RAC), a D2/D3/D4 receptor
antagonist, glutamatergic (MK-801, non-competitive NMDA receptor antagonist) and
GABAergic (muscimol and b acI of en , GABAA and GABAB receptor agonists
respectively) systems which showed a similar intake pattern to those of increased
response force requirement (i.e. decreased consumption at the 1 % sucrose solution
and increased consumption at the 32% solution). Administration of chlordiazepoxide
(CDP, a benzodiazepine anxiolytic) however, produced a non-specific increase at all
concentrations of sucrose. These results indicate a close interaction between DA,
GABA and glutamate in sucrose reward and anhedonia.
rHIFN-α is a cytokine used in the treatment of various viral illnesses. A major
limiting factor in the therapy is depression. Acute administration of rHIFN-α
decreased sucrose intake in a three-bottle test at all concentrations of sucrose,
although the effect was greater at 1 % solution. Chronic administration of rHIFN-α
decreased sucrose intake at the 1 % and increased that at the 32%. The increase in
consumption of the 32% solution was reversed by the chronic administration of a
tricyclic and selective serotonin reuptake inhibitor antidepressant. rHIFN-α however
failed to alter locomotor activity or amphetamine (AMP)-induced sensitisation.
Using in vitro voltammetry in brain slices, it was shown that peripheral pretreatment
with AMP led to increased levels of DA in the nucleus accumbens (NAcb)
core relative to the rats that had been treated with vehicle. rHlFN- α, reduced evoked
DA release in the NAcb core at all frequencies of stimulation. The administration of
anti-human lFN-cx, antibody (mHlFNAb) reversed the decrease in sucrose intake at the
32% solution produced by the acute administration of rHlFN-cx,. This strongly
suggests that the behavioural effects produced by lFN- α, may be related to these
central dopaminergic changes. These findings are discussed in relation to a
behavioural model for rHINF-α,-induced depression and relative to furthering our
understanding into the possible mechanisms through which rHIFN-α, may produce
depression in patients and possible therapeutic strategies to alleviate such.
Description: PH.D.2001-01-01T00:00:00Z